GlassScriptPhysician profile
Mark B Schabbing
NPI 1861584534
$8,763.19
in general payments reported to CMS, 2019-2025
34 companies · $1,349 in 2025
The $1,349 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $288 · 2020: $268 · 2021: $1,454 · 2022: $2,337 · 2023: $1,366 · 2024: $1,702 · 2025: $1,349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,396 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,395.78 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,347.49 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Lilly USA, LLC | $665.99 | 2019-2025 | Mounjaro, Trulicity, Jardiance |
| Novo Nordisk INC | $441.58 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $438.19 | 2021-2025 | |
| Amgen INC. | $323.74 | 2019-2025 | Evenity, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $276.44 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Astrazeneca Pharmaceuticals LP | $232.46 | 2022-2025 | Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $205.31 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $188.94 | 2019-2025 | Spravato |
| Allergan, INC. | $187.89 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $171.10 | 2022-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $168.27 | 2021-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Glaxosmithkline, LLC. | $157.30 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Biohaven Pharmaceutical Holding Company LTD. | $123.77 | 2022 | |
| Exact Sciences Corporation | $85.33 | 2024-2025 | Cologuard Collection Kit |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $77.90 | 2019-2024 | Veozah |
| Sunovion Pharmaceuticals INC. | $75.77 | 2021 | |
| Sumitomo Pharma America, INC. | $73.90 | 2023-2025 | Gemtesa |
| Amarin Pharma, INC. | $70.41 | 2020-2022 | |
| Abbott Laboratories | $61.38 | 2021-2023 | Freestyle Libre 2 |
| Pfizer INC. | $59.81 | 2020-2025 | |
| Phathom Pharmaceuticals, INC. | $58.92 | 2024-2025 | Voquezna |
| Medtronic, INC. | $57.87 | 2025 | Inceptiv |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.41 | 2025 | Caplyta |
| Dexcom, INC. | $32.88 | 2022-2025 | Dexcom G6 Transmitter |
| Eisai INC. | $32.43 | 2021 | |
| Lundbeck LLC | $16.28 | 2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $14.98 | 2025 | Uzedy |
| Sanofi Pasteur INC. | $14.16 | 2022 | |
| Alkermes, INC. | $14.11 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.79 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.75 | 2021 | |
| Supernus Pharmaceuticals, INC. | $11.84 | 2020 | |
| Mylan Specialty L.P. | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Schabbing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.